Acetic Acid, Chloro[(4-METHOXYPHENYL)Hydrazono]-, Ethyl Ester, (2Z)-, identified by its CAS number 473927-63-8, is a pivotal organic intermediate within the fine chemical and pharmaceutical industries. Its primary significance stems from its indispensable role in the complex synthetic pathway leading to Apixaban, a leading oral anticoagulant. This compound, a key building block in modern pharmacochemistry, is carefully synthesized to meet the stringent requirements of pharmaceutical manufacturing. As a critical precursor, the demand for CAS 473927-63-8 is directly linked to the global need for effective antithrombotic therapies, driving its importance in the supply chain for active pharmaceutical ingredients (APIs).

The chemical profile of Acetic Acid, Chloro[(4-METHOXYPHENYL)Hydrazono]-, Ethyl Ester, (2Z)- is defined by its formula C11H13ClN2O3 and a molecular weight of approximately 256.686 g/mol. It typically exists as a powder, which may range in color from white to yellowish. The specific (2Z)-isomer configuration is crucial for its reactivity and ability to impart the correct stereochemistry required later in the Apixaban synthesis. According to available data, its calculated density is around 1.231 g/cm³. The boiling point is estimated near 348.955 °C at standard atmospheric pressure, and the flash point is approximately 164.842 °C. These physical properties are important for safety data sheets and process engineering considerations. Pharmaceutical applications necessitate a high level of purity, typically specified at 98% or higher, confirmed through rigorous analytical testing methods.

Apixaban, widely known under trade names such as Eliquis, functions by inhibiting Factor Xa, a key enzyme in the blood clotting cascade. Its synthesis is a multi-step chemical process, where CAS 473927-63-8 serves as a foundational intermediate. This compound provides a specific chemical scaffold that undergoes subsequent reactions to form the final Apixaban molecule. The purity and structural integrity of the intermediate directly influence the yield, purity, and regulatory compliance of the final API. Any impurities or incorrect isomers carried over from the intermediate stage can lead to costly purification challenges or render the final product unsuitable for pharmaceutical use. Therefore, securing a supply of high-quality Acetic Acid, Chloro[(4-METHOXYPHENYL)Hydrazono]-, Ethyl Ester, (2Z)- is paramount for manufacturers aiming for efficient and compliant Apixaban production.

Ensuring the quality of pharmaceutical intermediates involves comprehensive testing and adherence to strict quality management systems. Analytical techniques play a vital role; High-Performance Liquid Chromatography (HPLC) is routinely used to assess purity and quantify impurities. Other methods like Gas Chromatography (GC), Nuclear Magnetic Resonance (NMR) spectroscopy for structural elucidation, and Mass Spectrometry (MS) for molecular weight and impurity identification are also critical tools. Manufacturers providing this intermediate for pharmaceutical use must issue a Certificate of Analysis (CoA) with each batch, detailing key analytical results. Moreover, compliance with principles akin to Good Manufacturing Practices (GMP), especially for intermediates leading to APIs, is increasingly expected to ensure traceability, consistency, and reliability throughout the supply chain.

While its primary application is in the synthesis of Apixaban, Acetic Acid, Chloro[(4-METHOXYPHENYL)Hydrazono]-, Ethyl Ester, (2Z)- is fundamentally a versatile organic intermediate. Its specific structure, featuring chloro, ester, and hydrazono functionalities adjacent to an activated carbon center and a methoxyphenyl group, allows it to participate in various chemical transformations. This makes it a valuable compound not only for established API routes but potentially also in research and development for novel pharmaceuticals or other fine chemicals where similar structural motifs are required. However, the scale of demand is overwhelmingly driven by the requirements of the global Apixaban market, making it a specialized commodity within the broader chemical industry.

Proper storage and handling procedures are essential to maintain the quality and stability of Acetic Acid, Chloro[(4-METHOXYPHENYL)Hydrazono]-, Ethyl Ester, (2Z)-. The material should be stored in tightly sealed containers to protect it from atmospheric moisture and oxygen. Storage in a cool, dry place, away from direct sunlight and heat sources, is recommended to prevent degradation or potential isomerization. Specific storage temperatures may be detailed in the product's Material Safety Data Sheet (MSDS), which also provides crucial information on handling precautions, safety measures, and emergency procedures. Understanding the material's flash point is important for fire safety assessments and ensuring appropriate ventilation in storage and handling areas.

The regulatory environment governing pharmaceutical intermediates is rigorous, focusing on quality, safety, and consistency. Suppliers must navigate complex international regulations to serve the global API market. The market dynamics for CAS 473927-63-8 are influenced by factors such as the patent landscape surrounding Apixaban, the production capacities of key manufacturers, and the stability of the raw material supply chain. Economic factors and geopolitical events can also impact pricing and availability. Manufacturers of Apixaban require a secure and reliable source of this intermediate to maintain consistent production output and meet market demand without interruption.

Procuring high-quality Acetic Acid, Chloro[(4-METHOXYPHENYL)Hydrazono]-, Ethyl Ester, (2Z)- requires a strategic approach to supplier selection. It is imperative to partner with entities that demonstrate a deep commitment to quality, possess robust manufacturing processes, and understand the specific demands of the pharmaceutical industry supply chain. Beyond the basic product specifications, factors such as supply chain reliability, consistency of batch quality, technical support, and comprehensive documentation are critical. Potential buyers often conduct audits of supplier facilities and quality systems to ensure alignment with their own standards and regulatory requirements. Establishing clear communication channels and building long-term relationships are beneficial in managing the supply of such a critical intermediate.

For those seeking a reliable manufacturer or supplier of this critical intermediate, due diligence is key. Inquiring about the current price per kilogram or for bulk quantities is a standard step in the procurement process. Potential customers should investigate the supplier's production capacity and lead times when planning a purchase. Considering options for a larger volume buy might offer cost efficiencies, but quality consistency across batches remains paramount. Access to necessary documentation, including Certificates of Analysis, Method of Analysis, and Material Safety Data Sheets, should be confirmed to ensure compliance and confidence in the material's quality for pharmaceutical synthesis.